{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:10:09Z","timestamp":1759972209780,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal des Maladies Vasculaires"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jmv.2015.05.006","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T14:22:14Z","timestamp":1435846934000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Art\u00e9riopathie des membres inf\u00e9rieurs d\u2019aggravation rapide chez un patient trait\u00e9 par nilotinib pour leuc\u00e9mie my\u00e9lo\u00efde chronique"],"prefix":"10.1016","volume":"40","author":[{"given":"V.","family":"Gautier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mirault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Azarine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Alsac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sapoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Messas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmv.2015.05.006_bib0095","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2015.05.006_bib0100","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmv.2015.05.006_bib0105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the second generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"year":"2011","series-title":"Commission de la transparence. Avis du 6\u00a0avril 2011","author":"HAS","key":"10.1016\/j.jmv.2015.05.006_bib0110"},{"key":"10.1016\/j.jmv.2015.05.006_bib0115","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","volume":"32","author":"European Stroke Organisation","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jmv.2015.05.006_bib0120","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2015.05.006_bib0125","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase. Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmv.2015.05.006_bib0130","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.92.92","article-title":"ENESTnd update. Nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes","volume":"122","author":"Saglio","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmv.2015.05.006_bib0135","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmv.2015.05.006_bib0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmv.2015.05.006_bib0145","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmv.2015.05.006_bib0150","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmv.2015.05.006_bib0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jmv.2015.05.006_bib0160","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmv.2015.05.006_bib0165","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmv.2015.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmv.2015.05.006_bib0175","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/leu.2014.342","article-title":"Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia","volume":"29","author":"Rea","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jmv.2015.05.006_bib0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V122.21.257.257","article-title":"Nilotinib exerts direct pro-atherogenic and antiangiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML","volume":"122","author":"Emir","year":"2013","journal-title":"Blood"}],"container-title":["Journal des Maladies Vasculaires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398049915001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398049915001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:14:01Z","timestamp":1759954441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0398049915001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0398049915001109"],"URL":"https:\/\/doi.org\/10.1016\/j.jmv.2015.05.006","relation":{},"ISSN":["0398-0499"],"issn-type":[{"type":"print","value":"0398-0499"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Art\u00e9riopathie des membres inf\u00e9rieurs d\u2019aggravation rapide chez un patient trait\u00e9 par nilotinib pour leuc\u00e9mie my\u00e9lo\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"Journal des Maladies Vasculaires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmv.2015.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}